Cassava Sciences said on Tuesday its Alzheimer's drug simufilam, which has been at the center of regulatory scrutiny, failed ...

Certain widely used drug combinations may either slow down or worsen the progression of Alzheimer's disease, but their ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...

(Reuters) -Cassava Sciences said on Tuesday it will discontinue the development of its experimental treatment simufilam for ...

A clinical trial involving individuals genetically predisposed to develop early-onset Alzheimer’s disease suggests that ...

NEW YORK (Reuters) -The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by ...

Research shows experimental anti-amyloid drug reduced cognitive symptom risk by 50% in people with rare genetic mutations ...

The drug, gantenerumab, was abandoned by its developers, but subsequent anti-amyloid drugs lecanemab ( Leqembi) and donanemab ...

While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 ...

Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

For the study, the researchers gave the study participants an experimental anti-amyloid drug. They found that 22 participants ...

An early Alzheimer's treatment that removes amyloid plaques from the brain many years before symptoms arise may help delay ...